Stopped: Sponsor Decision
The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS). The study will measure how often fasciculations occur, and monitor any side effects that might develop while taking the investigational product. Participants will be assessed before and after taking a single dose of FLX-787-ODT. Approximately 15 people will take part in this study at one center in the United States. Participants will be in the study for a single clinic visit and receive a telephone call 7 days later to monitor for side effects.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from Baseline of Diastolic Blood Pressure in mmHg
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
Change from Baseline of Systolic Blood Pressure in mmHg
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
Change from Baseline in Heart Rate in beats per minute
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
Change from Baseline in Respiration Rate in breaths per minute
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
Change from Baseline of Oral Cavity Examination
Timeframe: Prior to and twice within 4 hours following administration of investigational product on the clinic visit
Incidence of Treatment-Emergent Adverse Events
Timeframe: Prior to and following administration of investigational product on the clinic visit with AEs followed for 7 days after by telephone contact